This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Grzych, J.-M.
Right arrow Articles by Capron, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grzych, J.-M.
Right arrow Articles by Capron, A.

 Previous Article  |  Next Article 

Infect Immun, March 1998, p. 1142-1148, Vol. 66, No. 3
0019-9567/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Relationship of Impairment of Schistosome 28-Kilodalton Glutathione S-Transferase (GST) Activity to Expression of Immunity to Schistosoma mattheei in Calves Vaccinated with Recombinant Schistosoma bovis 28-Kilodalton GST

Jean-Marie Grzych,1,* Jan De Bont,2 Jinli Liu,1 Jean-Loup Neyrinck,1 Josette Fontaine,1 Jozef Vercruysse,2 and André Capron1

Centre d'Immunologie et de Biologie Parasitaire, Unité INSERM-U167, Institut Fédérarif de Recherche No. 17, Institut Pasteur de Lille, 59019 Lille, France,1 and Department of Parasitology, Faculty of Veterinary Medicine, University of Gent, B-9820 Merelbeke, Belgium2

Received 9 July 1997/Returned for modification 26 August 1997/Accepted 3 December 1997

Sera from calves vaccinated with the recombinant Schistosoma bovis-derived 28-kDa glutathione S-transferase (28GST) and subsequently naturally or experimentally exposed to Schistosoma mattheei were studied for their content of specific immunoglobulin G (IgG) and IgA antibodies to recombinant S. bovis 28GST as well as for their capacity to inhibit the enzymatic activity of the antigen. The results were analyzed in regard to the presence (natural infection) or absence (experimental infection) of a protective effect(s) (reductions in worm burden, egg load, fecal egg counts, and excretion of viable eggs) toward S. mattheei challenge. Under such conditions, no differences in the IgG- and IgA-specific antibodies to recombinant S. bovis 28GST or in the ability to block the catalytic function of the antigen between the two groups were recorded. Nevertheless, correlation analysis between the specific antibody responses to recombinant S. bovis 28GST and the inhibition of GST activity suggested an association with IgG in experimentally infected vaccinated animals, while in naturally infected vaccinated calves, the inhibitory activity appeared to be linked to a greater degree with IgA. These results suggest that in contrast to schistosomiasis in humans, IgG antibodies in calves with schistosomiasis may exhibit inhibitory functions toward GST enzymatic activity or have a modulatory effect on IgA antibody properties. Furthermore, sera from animals immunized with recombinant S. bovis 28GST recognized the native S. mattheei 28GST and achieved comparable levels of inhibition of activity of recombinant S. bovis 28GST and S. matthei 28GST, indicating the presence of cross-reactive epitopes on these two molecules.


* Corresponding author. Mailing address: Centre d'Immunologie et de Biologie Parasitaire, Unité INSERM-U167, IFR No. 17, Institut Pasteur de Lille, 1 rue du Pr Calmette, 59019 Lille, France. Phone: 33 03 20 87 79 61. Fax: 33 03 87 78 88. E-mail: jean-marie.grzych{at}pasteur-lille.fr.




This article has been cited by other articles:

  • Capron, A., Capron, M., Riveau, G. (2002). Vaccine development against schistosomiasis from concepts to clinical trials. Br Med Bull 62: 139-148 [Abstract] [Full Text]